相关实验视频
Updated: Jun 8, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
阿德罗是一种新型的内皮功能调节剂
Fina Lovren1, Yi Pan, Adrian Quan
1Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada.
Circulation
|September 15, 2010
概括
亚德罗蛋白增强内皮细胞功能,通过上调氧化 (NO) 合成酶,促进血管修复. 这表明阿德罗是内皮功能障碍疾病的潜在治疗标.
科学领域:
- 血管生物学 血管生物学
- 内分泌学 在内分泌学.
- 蛋白质信号传递的过程
背景情况:
- 阿德罗是一种新型蛋白质,与能量平衡和胰岛素抵抗有关.
- 血管功能和胰岛素敏感性是相互联系的.
- 阿德罗宾对内皮的直接影响仍然在很大程度上未被探索.
研究的目的:
- 为了研究adropin的潜在血管效应.
- 阐明参与阿德罗宾内皮细胞作用的信号通路.
- 评估adropin在小鼠缺血模型中的治疗潜力.
主要方法:
- 使用了体外内皮细胞培养和体内小鼠后肢缺血模型.
- 评估了内皮细胞的增殖,迁移,亡和毛细血管样管的形成.
- 研究的信号通路包括Akt,内皮氧化合成酶 (eNOS) 和血管内皮生长因子受体-2 (VEGFR2).
主要成果:
- 氨酸增强了内皮细胞的增殖,迁移和管形成,同时减少了细胞亡和透性.
- 阿德罗宾治疗通过VEGFR2,酸丁醇3-激酶 (PI3K) 和细胞外信号调节激酶1/2 (ERK1/2) 途径刺激了Akt和eNOS的酸化.
- 在体内,阿德罗改善了四肢输液,并在小鼠缺血模型中增加了毛细血管密度.
结论:
- 氨酸在内皮中表现出保护作用,可能是由PI3K-Akt和ERK1/2信号的VEGFR2-依赖激活的介导.
- 亚德罗宾可调节内皮氧化合成酶 (eNOS) 表达的表达,有助于其血管保护作用.
- 氨酸为涉及内皮功能障碍的疾病提供了一个新的治疗点,补充了其代谢益处.
相关概念视频
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

